BioMCC: Biotechnology Laboratory Microbial Culture Collection -BPPT Indonesia; ISP-2: Selective media 2 developed by Difco Laboratories for characterization of Streptomyces species; PDA: Potato Dextrose Agar; VEG: Liquid vegetative medium for cell proliferation of Streptomyces; FER: Liquid fermentative medium for Streptomyces; UHPLC-MS: Ultra High Performance Liquid ChromatographyMass Spectrophotometry; MW: Molecular weight (g.mol -1 ); NMR: Nuclear Magnetic Resonance; MetOH: Methanol; F1: The first group of fractions collected from the second silica gel column; F2: The second group of fractions collected from the second silica gel column; F3: The third group of fractions collected from the second silica gel column.
Introduction
Development of new antibiotic is a costly effort, while the risk of failure it brings is higher than those of other types of drugs; consequently only a few leading pharmaceutical companies are currently interested in developing new antibiotics. For example, GlaxoSmithKline reported that within the last 10 years of the 72 candidates of new antibiotic compounds that passed the first phase of clinical trials, only one antibiotic was approved by the FDA (Food and Drug Administrations, USA) [1, 2] . In addition, research on antifungal drugs against deadly invasive fungal infections also stagnated in which only a few companies are still involved [1] .
In the last 25 years, a steady increase of microbial resistance to antibiotics has become a serious threat to global public health. A search to discover new antibiotics has become an utmost important research program around the world because of the increase in resistance toxicity of some available antibiotics [1, 2] . Pharmaceutical industry is now facing a scarcity of new antibiotics; therefore, to ensure the availability of effective drugs in the future, it is important to increase efforts for identification of new antibiotics [3] . Development of new molecules with broad spectrum towards the target pathogen is an urgent need [1, 3] . High rates of antibiotic resistance due to inappropriate use of antibiotics have also triggered need of new antibiotics having different chemical structure and mechanism of action to the present antibiotics used in medication.
Filamentous actinomycetes, especially the genus Streptomyces is the producer of various natural metabolites [3] [4] [5] . These organisms have the ability to secrete various compounds with different biological activities, such as antibiotics, antitumor, antifungi, antituberculosis, as well as pesticides [4, 6] . Although Streptomyces is hardly rivaled by other bacterial groups in terms of the ability to produce natural antifungal metabolites, it is likely that chance to discover a new antifungal molecules from Streptomyces is now very low unless the proper strategy and adequate screening and isolation is applied [5, 7, 8] . Indonesian nature offers a potential source for isolation of newly Streptomyces derived antifungal compounds.
The majority of natural antibiotic substances are antibacterial and are indispensable to treat bacterial infections in humans, animals and plants [9] . In contrast, antifungal antibiotics for treating fungal infections are relatively few, mainly due to solubility and toxicity problems [9] [10] [11] . The increasing incidents of fungal infections in humans have directed attention to a search for novel antifungal antibiotics from actinomycetes having a broad spectrum of activity and lesser toxicity [12] .
One of our strains within Streptomyces group was isolated from Indonesian soil and screened for bioactive compound in 2006. This strain was preserved and kept in -80ºC until re-grown in 2015 for further studies of its potential as antifungal producer. In our earlier study, this strain showed broad and strong antifungal activities against all of tested mold and yeasts. The molecular identification done in 2015 revealed and designated its taxonomic name as Streptomyces herbaricolor BioMCC-a.RP-131. This paper describes the results of the isolation, purification and chemical structure examination of active antifungal compounds derived from fermentation of Streptomyces herbaricolor BioMCC-a.RP-131.
Materials and Methods

Microbial strains and materials
Streptomyces herbaricolor BioMCC-a.RP-131 as the producer of antifungal compound was maintained in agar slant ISP-2 (Merck) and Aspergillus niger for bioassay was maintained in agar slant PDA. Both strains were obtained from the stock culture of BioMCC (BPPT Indonesia). Unless otherwise stated, all chemicals used were of analytical grade.
Preparation of broth by shake flask fermentation
The spores of Streptomyces herbaricolor BioMCC-a.RP-131 grown on the agar slant ISP-2 (Difco) was taken 1x loopful and inoculated into 20 ml of vegetative medium, namely VEG, consisting of (per litre): 16 g corn steep liquor, 10 g glucose, 20 g sucrose, 2 g ammonium sulphate, 7 g calcium carbonate and water. After shaking at 28ºC, 150 rpm, 2.5 cm stroke, during 72 h, 5 ml of the vegetative culture was transferred to 50 ml of the fermentation medium, namely FER, in a 500 ml Erlenmeyer flask. The FER consisted of (per litre): 30 g cassava starch, 30 g soybean meal, 40 g dextrin, 2 g ammonium sulphate, 6 g calcium carbonate, 2 ml soybean oil and water. The total volume of the FER prepared was 2 L (this gave 40 flasks, each containing 50 ml of the FER). Fermentation was run for 8 days (192 h) at a temperature of 28ºC, 220 rpm and 2.5 cm stroke. During fermentation, 1 ml broth taken from a flask was centrifuged at 10,000 rpm for 10 minutes to obtain a cell-free filtrate, which was used for measuring antifungal activity by bioassay as described later.
Preparation of crude extract
Fermentation broth (2 L) was extracted with 2 litre n-butanol (1:1) by stirring with orbital shaker for 20 min. After extraction, organic phase (top layer) was separated from the aqueous phase by centrifugation at 10,000 rpm for 20 min. The organic phase was evaporated with a vacuum rotary evaporator at a temperature of 50-55ºC until the organic solvent completely evaporated, leaving a dried crude extract in a rotary evaporator flask. The dried crude extract obtained was 24 gm. The crude extract was stored in -20ºC if not immediately used for the separation.
Isolation and purification
Silica gel (50 g, 200-300 mesh, Merck), mixed with methanol, was packed in a glass column 2 cm in diameter, resulting in 31 cm bed height. The steps for isolation and purification of the active antifungal compounds were as follows. The pre-weighed crude extract was dissolved in semi-polar solvent (methanol or acetonitrile). Separation of the non-polar components was done by extraction using organic solvent with a low boiling point (<80ºC) immiscible with methanol or acetonitrile, i.e. n-hexane. Antifungal activity in both phases was examined by bioassays to confirm the availability antifungal components in the semi-polar solvent and to check the residual antifungal activity in the non-polar solvent. The active fraction was then fractionated in a gradient elution in the column of silica gel with two organic solvent. This stage could be performed 2-3 times depending on needs. Antifungal activity of each fraction was examined in bioassays to determine the fractions containing the active compound. The solvent of the active fraction was evaporated to obtain a powder of separated compounds.
Bioassay for antifungal detection
A 20 ml Potato dextrose agar medium (PDA, Merck) (kept liquid at 50ºC) in a tube (diameter 2.5 cm, length 15 cm) was suspended with 0.1 ml Aspergillus niger spores suspension in water (equivalent to 1 × 10 4 spores) and shaken gently, then poured into a sterile petri dish and allowed to solidify. Bioassay for measuring the antifungal activity was carried out by the so-called agar-plug method, done according to the following procedures. Wells on a PDA plate were made with the help of a rubber cork (metal made) having the diameter 6 mm. If not specified otherwise, as many as 40 µl sample was pipetted into a well. The test plates were incubated at 28ºC for 48-72 hours. The diameter of the inhibition zone (mold inhibition area) formed was measured. The inhibition zone diameter was measured with caliper (Mitutoyo, USA) three times in three different directions, and then averaged. The diameter of inhibition zone of a sample is the average value of two replicates (Duplo).
Examination of the chemical structure of active compound
The pattern of mass spectrum of the active compound was investigated by UHPLC-MS to ensure the molecular formula, molecular weight, and fragments resulted from the ionisation of antifungal molecules.
Results and Discussion
Fermentation broth preparation
From the bioassay test results, no antifungal activity was detected in the fermentation broth after 5 days, indicating that the culture was still in the logarithmic growth phase. The antifungal activity was detected on the seventh day of fermentation (Figure 1) , with the average diameter of inhibition zone was 17 mm. These results showed that long fermentation time (more than 5 days) is required to produce sufficient antifungal compound ready for isolation and purification. Fermentation accomplished for 8 days. The crude extract was prepared from the fermentation broth, has been described in Methods.
Isolation and purification of active compounds
First fractionation with silica gel column: Crude extract (0.75 g) was suspended with 5 ml of acetonitrile and was extracted with 5 ml of n-hexane (solvent immiscible with acetonitrile) for 20 min using a reciprocal shaker to separate non-polar components. The acetonitrile phase (bottom layer) was collected and dried in a vacuum concentrator to obtain 0.70 g dry solid. The solid was re-dissolved in 2 ml methanol for separation with silica gel column. Before sample loading, the silica gel column was firstly saturated with diethyleter-ethylacetat (19:1). The sample was then loaded into the silica gel column and elution in gradient was carried out successively using a mixture of diethyletherethylacetate in ratio, respectively, 19:1 (50 ml); 9:1 (50 ml); 4:1 (50 ml); 1:1 (50 ml); followed by ethylacetate-methanol in ratio, respectively, 19:1 (50 ml); 9:1 (50 ml); 6:4 (50 ml); 1:9 (50 ml); 0:1 (100 ml); followed by methanol-water in ratio 1:1 (100 ml).
Volume of each fraction collected was 7-8 ml. There were 81 fractions collected. Fraction 1-70 was dried by a vacuum concentrator (45ºC) for 2 h. Fraction 71-81 was dried overnight (16 h) at the same temperature. Visual appearance of the dried solid in the bottom of the tube of fraction is shown in Table 1 .
The absence of solids in fractions of 1-26 (Table 1) in which polarity of the mobile phase tend to be non-polar indicates that the non-polar components had been completely separated when the sample was treated with with n-hexane. Furthermore, fraction 1-26 was disposed; whereas fraction of 27-81 each was re-dissolved with 2 ml methanol. The antifungal activity soluble fraction was measured by bioassay (Figure 2) . The average diameters of inhibition zone are shown in Table 2 .
It is clearly seen in Table 2 that the active component was detected in the fraction when polarity of the solvent (mobile phase) turned high. This implies that the active component must be a semi-polar compound. Based on data in Table 2 , the fraction 27-54 and 56-58 were discarded. For further separation, the remained fractions were grouped according to the trend of inhibition zone diameter as follows: Group-1 (fraction 55, 59, 60, 61 and 62), Group-2 (fraction 63-68), Group-3 (fraction 69-78), Group-4 (fraction 79-81). Among the groups, the inhibition zone diameter of any single fraction within Group-2 was generally higher than any single fraction in the other groups, therefore Group-2 was chosen for second fractionation.
Second fractionation with silica gel column:
The silica gel column was firstly saturated with ethylacetate-methanol (9:1). The solid in tubes from Group-2 were successively dissolved and rinsed with 0.5 ml methanol as much as six times, thereby the total volume of methanol used was 3 ml. Then, 0.3 ml of glacial acetic acid was added to acidify the sample. The sample was loaded into the silica gel column and elution in gradient was carried out successively using a mixture of ethylacetatemethanol in ratio 9:1 (100 ml); 8:2 (50 ml); 6:4 (50 ml); 4:6 (50 ml); 2:8 (50 ml); 1:9 (50 ml); 0:1 (200 ml).
Volume of each fraction collected was 9-10 ml. There were 58 fractions collected. Fractions were dried by a vacuum concentrator (45ºC) overnight (16 h). Visual appearance of the dried solid in the bottom of the tube of fraction is shown in Table 3 .
Fraction
Visual appearance Applied to all fractions, each fraction was dissolve with 2 ml methanol and subjected to bioassay (no replicate). Sample volume per well in PDA agar plate for bioassay was 20 µl. The inhibition zones are shown in Table 4 .
Based on data in Table 4 , the fraction 1-21 and 53-58 were discarded. For further analysis, the remained fractions were grouped according to the trend of inhibition zone diameter as follows: F1 (fraction 22-38), F2 (fraction 39-48), F3 (fraction 49-52).
Solid in group was diluted and collected with water and methanol as follows: the fractions within each group was dissolved and rinsed consecutively with 0.5 ml of water (2 times) and 0.5 ml of methanol (2 times) so that the total volume of water-methanol solvent used to dissolve all solid in each group was 2 ml. The bioassay results (Figure 3) shows that the diameter of inhibition zone from high to low is drawn F2>F3>F1.
Chemical structure examination using UHPLC-MS
Because the diameter of inhibition zone of F1 was relatively small, this sample was not examined by UHPLC-MS. Samples examined were F2 and F3. Figure 4 depicts a comparison of UHPLC chromatograms of methanol alone (solvent), F2 and F3.
By comparing UHPLC chromatograms of methanol, F2 and F3 (Figure 4) , any peak which is absent in the methanol chromatogram but found in either F2 or F3 chromatograms was considered as the suspected peaks of antifungal compounds. Those suspected peaks were chosen for MS analysis. The selected peak for F2 is at 3.73 and 4.06 min. The selected peak for F3 is at 3.16; 3.50; 3.73; and 4.07 min. These results imply that after two steps of column chromatography separation, F2 and F3 still contained at least 2 and 4 components, respectively. In other words, those samples did not contain single compound yet.
The MS spectrum of F2 for peak 3.73 and 4.06 min can be seen in Figure 5 . The summary of the element composition of F2 and the number of possible chemical structures of the corresponding chemical formula can be seen in Table 5 . Similarly, the MS spectrum of F3 for peak 3.16; 3.50; 3.73; and 4.07 min can be seen in Figure 6 . The summary of the element composition of F3 and the number of possible chemical structures of the corresponding chemical formula can be seen in Table 6 . t has been shown so far that it is very difficult to estimate the chemical structure of antifungal antibiotic if the samples analyzed did not contain a single compound (or pure compound). However, we are very interested to the component in F2 having the UHPLC peak at 3.73 min with the chemical formula C 39 H 39 N 4 (MW 562.3175 g.mol -1 ), in which no chemical structure has been reported in Chemspider yet for this formula, suggesting it to be a new compound. It is therefore becoming a challenge for us to elucidate the structure of this compound. 
